Whether seeking injury recovery, muscle growth, gut health improvements, or general anti-inflammatory advantages, scheduling should be aligned with individual goals
Eliza Sun, Executive Director at Hansoh Pharma, said olatorepatides dual-target design delivers strong weight-loss efficacy while showing improved gastrointestinal tolerability, with nausea below 10% and vomiting below 5%, a profile that could support better long-term treatment adherence in people with overweight or obesity
Content Lose some, win some Reviewed by Mike Bohl, MD Written by Vanessa Gibbs Published 12/17/2024 Updated 07/08/2025 Hims and Found are both telehealth companies offering access to prescription medication and support to help people with excess weight and obesity lose weight
doi: 10.1111/1523-1747.ep12476735
sporadic use limits efficacy